Drug Information

General Information
Drug ID
DR00106
Drug Name
Tetraethylammonium
Synonyms
4-04-00-00331 (Beilstein Handbook Reference); 56-34-8 (chloride); 5AV7G7EIEE; 66-40-0; 68-05-3 (iodide); 71-91-0 (bromide); 77-98-5 (hydroxide); AC1L1KAW; AMMONIUM, TETRAETHYL-; BRN 1738225; C8H20N; CHEBI:44296; CHEMBL9324; Ethanaminium; GTPL2343; GTPL4575; Lopac-T-2265; N,N,N-Triethylethanaminium; NEt4(+); SCHEMBL16267; TETRAETHYLAMMONIUM ION; Tetraethylammonium; Tetraetilammonio; Tetraetilammonio [Italian]; Tetramon; Tetrylammonium; UNII-5AV7G7EIEE; [14C]-TEA; [14C]TEA; tetraethyl ammonium; tetraethylamine; tetraethylazanium
Drug Type
Small molecular drug
Indication Hyperlipidaemia [ICD11:5C8Z] Phase 2 [1]
Structure
3D MOL 2D MOL
Formula
C8H20N+
Canonical SMILES
CC[N+](CC)(CC)CC
InChI
InChI=1S/C8H20N/c1-5-9(6-2,7-3)8-4/h5-8H2,1-4H3/q+1
InChIKey
CBXCPBUEXACCNR-UHFFFAOYSA-N
CAS Number
CAS 66-40-0
Pharmaceutical Properties Molecular Weight 130.25 Topological Polar Surface Area 0
Heavy Atom Count 9 Rotatable Bond Count 4
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 0
XLogP
1.7
PubChem CID
5413
PubChem SID
103168691 ,104037965 ,104309173 ,106812165 ,11111868 ,124750303 ,124881591 ,125659879 ,126677961 ,126678584 ,127299839 ,127299840 ,127299841 ,127299842 ,127299843 ,127299844 ,127299845 ,127299846 ,127299847 ,127299848 ,127299849 ,127299850 ,127299851 ,127299852 ,127299853 ,127602502 ,127838406 ,1434686 ,15297244 ,24263038 ,26697167 ,29224465 ,37356638 ,49868992 ,50111261 ,53790517 ,560558 ,561143 ,5617425 ,57322763 ,6903206 ,76453784 ,7887259 ,7889355 ,8002309 ,8153330 ,823293 ,823821 ,90340838 ,9715
ChEBI ID
CHEBI:44296
TTD Drug ID
D06PZZ
DT(s) Transporting This Drug 1-Oct Transporter Info Organic cation transporter 1 Substrate [2]
2-Oct Transporter Info Organic cation transporter 2 Substrate [3]
MATE1 Transporter Info Multidrug and toxin extrusion protein 1 Substrate [4]
MATE2 Transporter Info Multidrug and toxin extrusion protein 2 Substrate [5]
OCTN1 Transporter Info Organic cation/carnitine transporter 1 Substrate [6]
Drug-Transporter Activity Data
Drug-Transporter Activity Data 1-Oct Transporter Info Km =229 microM Human cervical cancer cell line (Hela)-OCT1 [7]
1-Oct Transporter Info Km =566 microM Proximal tubule (S2) cells-OCT1 [2]
2-Oct Transporter Info Km =63 microM Human embryonic kidney cells (HEK293)-OCT2 [8]
2-Oct Transporter Info Km =431 microM Human embryonic kidney cells (HEK293)-OCT2 [8]
2-Oct Transporter Info Km =33.8 microM Oocytes-OCT2 [3]
2-Oct Transporter Info Km =31 microM Oocytes-OCT2 [9]
2-Oct Transporter Info Km =76 microM Oocytes-OCT2 [9]
MATE1 Transporter Info Km =220 microM Human embryonic kidney cells (HEK293)-MATE1 [4]
MATE1 Transporter Info Km =380 microM Human embryonic kidney cells (HEK293)-MATE1 [10]
MATE2 Transporter Info Km =760 microM Human embryonic kidney cells (HEK293)-MATE2K [5]
MATE2 Transporter Info Km =830 microM Human embryonic kidney cells (HEK293)-MATE2K [11]
OCTN1 Transporter Info Km =436 microM Human embryonic kidney cells (HEK293)-OCTN1 [12]
OCTN1 Transporter Info Km =1800 microM Human embryonic kidney cells (HEK293)-OCTN1 [6]
OCTN1 Transporter Info Km =195 microM Oocytes-OCTN1 [12]
References
1 ClinicalTrials.gov (NCT00166166) Endothelial Hyperpolarization in Humans
2 Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos. 2009 Sep;37(9):1856-63.
3 Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
4 A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8.
5 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
6 Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
7 Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61.
8 cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10.
9 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
10 The role of microRNA in the delayed negative feedback regulation of gene expression. Biochem Biophys Res Commun. 2007 Jul 6;358(3):722-6.
11 Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006 Aug;17(8):2127-35.
12 Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.